PRESS RELEASE published on 09/09/2024 at 22:01, 1 year 10 months ago Abivax presents first-half 2024 financial results Abivax presents first-half 2024 financial results with a cash balance of EUR 222M at June 30, 2024. The company focuses on developing therapies for chronic inflammatory diseases Financial Results Abivax Therapeutics Chronic Inflammatory Diseases EUR 222M
BRIEF published on 08/29/2024 at 18:05, 1 year 11 months ago ABIVAX: Status of shares and voting rights as of July 31, 2024 Euronext Paris Voting Rights Actions Abivax Regulatory
BRIEF published on 08/06/2024 at 08:35, 1 year 11 months ago Abivax Reaches Key Milestone with Recruitment of 600 Patients for Phase 3 ABTECT Trial Patient Recruitment Abivax Obefazimod Ulcerative Colitis Clinical Test
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 11 months ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
BRIEF published on 07/23/2024 at 18:05, 2 years ago ABIVAX: Number of shares and voting rights as of June 30, 2024 Voting Rights Euronext Actions AMF Abivax
BRIEF published on 07/23/2024 at 18:05, 2 years ago ABIVAX: Half-yearly review of the liquidity contract as of June 30, 2024 Liquidity Contract Actions Financial Transactions Abivax First Half Of 2024
BRIEF published on 07/22/2024 at 09:51, 2 years ago Threshold crossing by Deep Track Biotechnology Master Fund Voting Rights Abivax Crossing Threshold Off-market Acquisition Deep Track Biotechnology
BRIEF published on 07/15/2024 at 22:05, 2 years ago Abivax announces advances in its clinical program and updates its operations Treasury Ulcerative Colitis Nomination Update Clinical Program
PRESS RELEASE published on 07/15/2024 at 22:00, 2 years ago Abivax Provides Operational and Key Program Update Abivax provides operational and key program update, including progress on clinical trials, leadership changes, and financial update Leadership Changes Abivax Clinical Trials Operational Update Financial Update
BRIEF published on 06/28/2024 at 18:05, 2 years 1 month ago ABIVAX: Summary of the Number of Shares and Voting Rights as of May 31, 2024 Voting Rights Actions AMF Abivax Transparency
Published on 08/01/2026 at 01:20, 1 day 14 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 1 day 14 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 1 day 15 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 1 day 16 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/02/2026 at 08:15, 7 hours 31 minutes ago Holcim signs agreement to divest its business in the Philippines
Published on 08/01/2026 at 16:35, 23 hours 10 minutes ago HIZENERGY Enters Global Top Tier with BloombergNEF Tier 1 Listing
Published on 07/31/2026 at 19:55, 1 day 19 hours ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA Reaches Agreement with Financing Partners on Extension of Standstill Agreement and Continuation of Restructuring Process
Published on 07/31/2026 at 19:05, 1 day 20 hours ago Eurobattery Minerals presents the Q2 report for 2026 as the Company accelerates the development of the San Juan tungsten project
Published on 07/31/2026 at 21:00, 1 day 18 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:13, 1 day 20 hours ago Covivio - Information on Treasury shares transactions between July 29th, 2026 and July 31st, 2026
Published on 07/31/2026 at 18:30, 1 day 21 hours ago Covivio Hotels - 2026 Half-year financial report
